Pay in 4 interest-free payments of $6.49 Learn more
Ships within 48 hours · Estimated delivery Aug 10 - Aug 15
Table of Contents Jardiance (Empagliflozin) Product Category Diabetes & Heart Failure SGLT2 Inhibitor Generic Name or Biosimilar No Active Ingredient Empagliflozin Prescription Status Prescription-only Targeted Conditions Jardiance is approved to treat the following conditions: Type 2 Diabetes Mellitus (T2DM), to improve glycemic control Heart Failure with Reduced Ejection Fraction (HFrEF), to reduce the risk of cardiovascular death and hospitalization Chronic Kidney Disease (CKD), to slow progression and improve renal outcomes Off-Label Usage Some off-label uses being studied or prescribed include: Heart Failure with Preserved Ejection Fraction (now formally approved) Type 1 Diabetes (investigational
When whole-food protein intake is consistently suppressed by GLP-1 therapy, a free-form EAA supplement can help maintain EAA availability without the caloric load or digestive demand of a full protein shake
In the highly competitive cattle feed industry, profitability is determined long before the product reaches the farmer
Women with obesity and/or diabetes (the population using GLP-1 medications) already face higher pregnancy complication rates even without medication
If you are curious about the math for that medication, our semaglutide dosage in units guide uses the same approach
